SELLAS Life Sciences Group, Inc.

SELLAS Life Sciences Group, Inc.

SLSNYSE / NASDAQHealthcareSmall cap

$13.66-$1.20 (-8.1%)

Last close · Data as of Nov 20, 2026

Market cap
$1.8B
P/E
-66.2x
EV / EBITDA
-60.4x
Revenue
$0.00
ROCE
-39.6%

This period includes a one-day price step on 17 Nov 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

SELLAS Life Sciences Group, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
Hidden
3M
Hidden
6M
Hidden
1Y
Hidden
5Y
Hidden
  • This period includes a one-day price step on 17 Nov 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

This period includes a one-day price step on 17 Nov 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Day change -$1.20 (-8.1%) from $14.86 to $13.66 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in SLS, bought on each weekday since 2021.

News & filings

What SELLAS Life Sciences Group filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 26.9 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are more than ten times current liabilities.
  • Revenue is too small for margins and growth rates to be read, so those points are not shown.
  • This period includes a one-day price step on 17 Nov 2026 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Read moreShow less

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Sector
Healthcare
Shares outstanding
153.1M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.8B
P/E
-66.2x
P/B
25.1x
EV / EBITDA
-60.4x
52-week high
Hidden
52-week low
Hidden

Profitability

ROE
-37.9%
ROCE
-39.6%
ROIC
-28274.0%
ROA
-34.3%

Growth

Revenue
$0.00
Net profit growth, 1Y
-13.0%
Free cash flow
-$28.4M

Solvency

Current ratio
10.72
Debt / Equity
0.01
Debt / Assets
0.01
CFO / Net profit
1.06
Cash / Market cap
4.0%

Revenue and net profit

Annual revenue, with net profit as the dashed line.

SELLAS Life Sciences Group, Inc. revenue and net profit by fiscal year
SELLAS Life Sciences Group, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$1.0M-$41.3M
FY2023$0.00-$37.3M
FY2024$0.00-$30.9M
FY2025$0.00-$26.9M

Cash flows

FY2025: -$28.4M from operations, -$28.4M free after investment (dashed).

SELLAS Life Sciences Group, Inc. operating and free cash flow by fiscal year
SELLAS Life Sciences Group, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$23.8M-$28.3M
FY2023-$31.4M-$36.9M
FY2024-$35.4M-$35.4M
FY2025-$28.4M-$28.4M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$0.00
EBITDA
-$28.3M
Net profit
-$26.9M
Cash from operations
-$28.4M
Free cash flow
-$28.4M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$0.00-$28.3M-$26.9M-$28.4M-37.9%—-13.0%

Monthly returns

Month-by-month returns of SLS across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$78.3M
Liabilities$7.5M
Equity$70.9M
Paid-in capital$345.8M
Retained earnings-$275.0M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; SLS highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

Not shown (no positive earnings and no EV / Sales): SELLAS Life Sciences Group, Inc., Rapport Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
SELLAS Life Sciences Group, Inc.SLSthis company$1.8B-66.2x25.1x-37.9%-60.4x
Pediatrix Medical Group, Inc.MD$1.8B11.1x2.1x19.1%7.6x
Viridian Therapeutics, Inc.VRDN$1.8B-5.3x3.1x-58.1%-4.9x
Vericel CorporationVCEL$1.8B110.3x5.1x4.7%60.3x
ANI Pharmaceuticals, Inc.ANIP$1.8B23.0x3.3x14.5%10.3x
Nuvation Bio Inc.NUVB$1.8B-8.8x5.9x-66.9%-9.0x
Rapport Therapeutics, Inc.RAPP$1.8B—-178.2x-23.0%—
Surgery Partners, Inc.SGRY$1.8B-23.0x1.0x-4.5%9.9x
UFP Technologies, Inc.UFPT$1.7B25.4x4.1x16.1%16.8x
Peer median—11.1x3.2x0.1%9.9x

Year-to-date ROI

SLS since 1 January, against earlier years.

Historical volatility

SLS's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

SELLAS Life Sciences Group, Inc. operating margin by fiscal year
SELLAS Life Sciences Group, Inc. operating margin by fiscal year
DateOperating margin
FY2022-3195.0%
FY2023—
FY2024—
FY2025—
LineFY2025
Cost of revenueCost Of Revenue—
Gross profitGross Profit—
Operating expensesOperating Expense$28.3M
Research and developmentResearch And Development$16.0M
Total expensesTotal Expenses$28.3M
Pretax incomePretax Income-$26.9M

Learn while you research

Academy chapters picked for SELLAS Life Sciences Group, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →